Anti-adalimumab Antibodies in Patients with Non-infectious Ocular Inflammatory Disease: A Case Series.
K Matthew McKayNicholas ApostolopoulosBrian ChouThellea K LevequeRussell N Van GelderPublished in: Ocular immunology and inflammation (2021)
For patients receiving adalimumab for ocular inflammatory disease, a disease flare in the setting of previously well-controlled disease should prompt consideration of AAA testing.